Page last updated: 2024-09-03
marimastat and methane
marimastat has been researched along with methane in 1 studies
Compound Research Comparison
| Studies (marimastat) | Trials (marimastat) | Recent Studies (post-2010) (marimastat) | Studies (methane) | Trials (methane) | Recent Studies (post-2010) (methane) |
|---|---|---|---|---|---|
| 215 | 28 | 53 | 39,142 | 249 | 26,184 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Begay, JG; Campen, MJ; Denson, JL; Erdely, A; Fraser, K; Herbert, G; Hunter, R; Lucas, SN; Mostovenko, E; Ottens, AK; Salazar, R; Wang, T; Young, TL; Zychowski, K | 1 |
Other Studies
1 other study(ies) available for marimastat and methane
| Article | Year |
|---|---|
Pulmonary delivery of the broad-spectrum matrix metalloproteinase inhibitor marimastat diminishes multiwalled carbon nanotube-induced circulating bioactivity without reducing pulmonary inflammation.
Topics: Animals; Bronchoalveolar Lavage Fluid; Endothelial Cells; Hydroxamic Acids; Lung; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Nanotubes, Carbon; Pneumonia | 2021 |